title: Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.
abstract: Recent studies of the spectrum of somatic genetic alterations in acute myeloid leukemia (AML) have identified frequent somatic mutations in genes that encode proteins important in the epigenetic regulation of gene transcription. This includes proteins involved in the modification of DNA cytosine residues and enzymes which catalyze posttranslational modifications of histones. Here we describe the clinical, biological, and therapeutic relevance of mutations in epigenetic regulators in AML. In particular, we focus on the role of loss-of-function mutations in TET2, gain-of-function mutations in IDH1 and IDH2, and loss-of-function mutations in ASXL1 and mutations of unclear impact in DNMT3A in AML pathogenesis and therapy. Multiple studies have consistently identified that mutations in these genes have prognostic relevance, particularly in intermediate-risk AML patients, arguing for inclusion of mutational testing of these genetic abnormalities in routine clinical practice. Moreover, biochemical, biological, and epigenomic analyses of the effects of these mutations have informed the development of novel therapies which target pathways deregulated by these mutations. Our understanding of the effects of these mutations on hematopoiesis and potential for therapeutic targeting of specific AML subsets is also reviewed here.
authors: Human Oncology and Pathogenesis Program, and Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors: Omar
authors: O
authors: Abdel-Wahab
authors: Ross L
authors: RL
authors: Levine
mesh_terms: D000818:Animals; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics*; D000090205:DNA Methyltransferase 3A; D004268:DNA-Binding Proteins / Q000235:genetics*; D049308:Dioxygenases; D044127:Epigenesis, Genetic; D060045:Genes, Modifier / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000628:therapy*; D008957:Models, Genetic; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics*
chemical_list: D004268:DNA-Binding Proteins; C000717967:DNMT3A protein, human; D011518:Proto-Oncogene Proteins; D049308:Dioxygenases; C541081:TET2 protein, human; D004248:DNA (Cytosine-5-)-Methyltransferases; D000090205:DNA Methyltransferase 3A
references: Blood. 2010 Jan 7;115(1):38-46
references: 19861679
references: Hematol Oncol. 2011 Sep;29(3):157-60
references: 21922510
references: Nat Genet. 2011 Dec 04;44(1):23-31
references: 22138693
references: Leukemia. 2013 Jan;27(1):82-91
references: 23018865
references: Nature. 2009 Dec 10;462(7274):739-44
references: 19935646
references: Cancer Cell. 2010 Dec 14;18(6):553-67
references: 21130701
references: J Clin Oncol. 2010 May 10;28(14):2348-55
references: 20368543
references: Cell Cycle. 2011 Aug 1;10(15):2428-36
references: 21750410
references: J Clin Oncol. 2010 Aug 1;28(22):3636-43
references: 20567020
references: Cancer Res. 2002 Jul 15;62(14):4075-80
references: 12124344
references: Science. 2012 Sep 21;337(6101):1541-6
references: 22878500
references: Blood. 2011 Nov 17;118(20):5593-603
references: 21881046
references: Blood. 2010 Sep 23;116(12):2122-6
references: 20538800
references: Blood. 2009 Jul 2;114(1):144-7
references: 19420352
references: Blood. 2012 Feb 2;119(5):1208-13
references: 22053108
references: J Am Chem Soc. 2009 Dec 9;131(48):17536-7
references: 19950987
references: Oncogene. 2010 Jun 24;29(25):3723-31
references: 20400977
references: Nat Rev Cancer. 2007 Nov;7(11):823-33
references: 17957188
references: Leukemia. 2011 Oct;25(10):1570-7
references: 21647154
references: Cancer Cell. 2011 Jul 12;20(1):66-78
references: 21741597
references: Cancer Cell. 2011 Jul 12;20(1):53-65
references: 21741596
references: Leukemia. 2011 Jul;25(7):1147-52
references: 21494260
references: J Clin Oncol. 2011 Apr 1;29(10):1373-81
references: 21343549
references: J Am Chem Soc. 2011 Oct 26;133(42):16746-9
references: 21936531
references: Cancer Cell. 2012 Apr 17;21(4):473-87
references: 22464800
references: Nature. 2012 Dec 6;492(7427):108-12
references: 23051747
references: N Engl J Med. 2010 Dec 16;363(25):2424-33
references: 21067377
references: Nature. 2011 Oct 02;478(7370):529-33
references: 21964340
references: J Clin Oncol. 2011 Jul 20;29(21):2889-96
references: 21670448
references: Cancer Cell. 2010 Mar 16;17(3):225-34
references: 20171147
references: Sci Transl Med. 2012 Aug 29;4(149):149ra118
references: 22932223
references: J Am Chem Soc. 2010 May 19;132(19):6827-33
references: 20415477
references: Blood. 2009 Oct 15;114(16):3448-58
references: 19652201
references: Leukemia. 2010 Feb;24(2):469-73
references: 19865112
references: J Biol Chem. 2006 Jun 30;281(26):17588-98
references: 16606617
references: N Engl J Med. 2012 Mar 22;366(12):1079-89
references: 22417203
references: Blood. 2012 Aug 2;120(5):1107-17
references: 22677129
references: Nature. 2012 Aug 16;488(7411):404-8
references: 22842901
references: Blood. 2011 Oct 27;118(17):4509-18
references: 21803851
references: Oncogene. 2013 Feb 14;32(7):930-8
references: 22469984
references: Nat Chem Biol. 2012 Nov;8(11):890-6
references: 23023262
references: Nat Med. 2012 Mar 11;18(4):605-11
references: 22406747
references: Nature. 2010 Dec 9;468(7325):839-43
references: 21057493
references: N Engl J Med. 2012 Aug 16;367(7):647-57
references: 22894577
references: Blood. 2011 Jul 14;118(2):409-12
references: 21596855
references: Nature. 2011 Aug 03;478(7370):524-8
references: 21814200
references: Science. 2009 May 15;324(5929):930-5
references: 19372391
references: Blood. 2010 Jul 29;116(4):614-6
references: 20421455
references: Nat Genet. 2011 Mar 13;43(4):309-15
references: 21399634
references: Cancer Cell. 2011 Jul 12;20(1):11-24
references: 21723200
references: Leukemia. 2010 May;24(5):1062-5
references: 20182461
references: Blood. 2012 Jun 14;119(24):5615-7
references: 22700693
references: Cancer Cell. 2012 Aug 14;22(2):180-93
references: 22897849
references: Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33
references: 22396593
references: Hematol Oncol Clin North Am. 2011 Dec;25(6):1119-33
references: 22093580
references: J Biol Chem. 2010 Jan 1;285(1):18-29
references: 19880879
references: Blood. 2011 Dec 22;118(26):6920-9
references: 22031865
references: Cancer Cell. 2011 Jul 12;20(1):25-38
references: 21723201
references: Nature. 2012 Aug 30;488(7413):656-9
references: 22763442
references: Cancer Cell. 2011 Jan 18;19(1):17-30
references: 21251613
references: Leukemia. 2011 Nov;25(11):1704-10
references: 21647152
references: Blood. 2010 Apr 8;115(14):2749-54
references: 20097881
references: Blood. 2010 Oct 14;116(15):2779-82
references: 20651067
references: J Clin Oncol. 2010 Aug 10;28(23):3717-23
references: 20625116
references: Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14566-71
references: 21873190
references: J Am Chem Soc. 2010 Mar 10;132(9):3164-76
references: 20148560
references: Blood. 2011 Oct 6;118(14):3803-10
references: 21828143
references: J Clin Oncol. 2012 Mar 1;30(7):742-50
references: 22291079
references: Br J Haematol. 2009 Jun;145(6):788-800
references: 19388938
references: Blood. 2012 Jun 14;119(24):5824-31
references: 22490330
references: Nature. 2010 May 13;465(7295):243-7
references: 20436459
references: Nature. 2011 May 19;473(7347):398-402
references: 21460836
references: Blood. 2009 Feb 5;113(6):1315-25
references: 18832655
references: Nat Genet. 2012 Nov;44(11):1179-81
references: 23001125
references: Nat Genet. 2010 Aug;42(8):722-6
references: 20601953